Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Curr Med Chem. 2020; 27(27):4536-4541.CM

Abstract

Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease-19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir [which is widely used to treat Human Immunodeficiency Virus (HIV) infection] in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies.

Authors+Show Affiliations

Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy.School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy.Instituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I-80134 Naples, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32297571

Citation

Costanzo, Michele, et al. "SARS-CoV-2: Recent Reports On Antiviral Therapies Based On Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus." Current Medicinal Chemistry, vol. 27, no. 27, 2020, pp. 4536-4541.
Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020;27(27):4536-4541.
Costanzo, M., De Giglio, M. A. R., & Roviello, G. N. (2020). SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Current Medicinal Chemistry, 27(27), 4536-4541. https://doi.org/10.2174/0929867327666200416131117
Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports On Antiviral Therapies Based On Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020;27(27):4536-4541. PubMed PMID: 32297571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. AU - Costanzo,Michele, AU - De Giglio,Maria Anna Rachele, AU - Roviello,Giovanni Nicola, PY - 2020/02/13/received PY - 2020/03/27/revised PY - 2020/04/04/accepted PY - 2020/4/17/pubmed PY - 2020/8/12/medline PY - 2020/4/17/entrez KW - COVID-19 KW - Coronavirus KW - SARS-CoV-2 KW - antiviral drugs KW - favipiravir KW - hydroxychloroquine KW - lopinavir KW - remdesivir KW - ritonavir SP - 4536 EP - 4541 JF - Current medicinal chemistry JO - Curr Med Chem VL - 27 IS - 27 N2 - Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease-19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir [which is widely used to treat Human Immunodeficiency Virus (HIV) infection] in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies. SN - 1875-533X UR - https://www.unboundmedicine.com/medline/citation/32297571/SARS_CoV_2:_Recent_Reports_on_Antiviral_Therapies_Based_on_Lopinavir/Ritonavir_Darunavir/Umifenovir_Hydroxychloroquine_Remdesivir_Favipiravir_and_other_Drugs_for_the_Treatment_of_the_New_Coronavirus_ L2 - https://www.eurekaselect.com/181009/article DB - PRIME DP - Unbound Medicine ER -